DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
DXCARTES
Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX recurrence score*(RS) 18-25 or 26-100. Analyisis of RS changes at surgery (DXCARTES trial)
BREAST
ESMO Open
2024
DEMETHER
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER PATIENTS (DEMETHER).
BREAST
SABCS
2024
I3LUNG
The impact of decision tools during oncological consultation with lung cancer patients: a systematic-review within the i3LUNG project
LUNG
(Journal) Cancer Medicine
2024
I3LUNG
I3LUNG: Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
LUNG
ESMO
2024
TUXEDO-3
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.
LUNG
ASCO
2024
DEBBRAH
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
BREAST
(Journal) ESMO Open
2024
I3LUNG
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project
LUNG
(Journal) Nature Cancer
2024
OPHELIA
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: the OPHELIA phase 2 study
BREAST
(Journal) The Breast
2024
PHERGAIN
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
BREAST
(Journal) The Journal of Nuclear Medicine
2024
ABIGAIL
ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
BREAST
ESMO
2024
DEBBRAH
A multicenter, open-label, single-arm, multicohort phase II clinical trial of trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC) with brain metastases and/or leptomeningeal carcinomatosis (LMC) – The DEBBRAH study
BREAST
SNO/ASCO Brain Metastases Conference
2024
METSGAIN
Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial
BREAST
AACR
2024
Other MEDSIR related articles
"